Legal & General Group Plc Buys 10,211 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Legal & General Group Plc raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 106,767 shares of the company’s stock after buying an additional 10,211 shares during the period. Legal & General Group Plc’s holdings in Intellia Therapeutics were worth $1,245,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in NTLA. Barclays PLC boosted its holdings in Intellia Therapeutics by 17.7% in the third quarter. Barclays PLC now owns 292,795 shares of the company’s stock valued at $6,017,000 after acquiring an additional 44,022 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at $417,000. Franklin Resources Inc. boosted its stake in shares of Intellia Therapeutics by 10.3% in the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after purchasing an additional 1,538 shares during the last quarter. Green Alpha Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth $138,000. Finally, AdvisorNet Financial Inc raised its stake in Intellia Therapeutics by 96.4% during the fourth quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock worth $118,000 after buying an additional 4,950 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

NTLA has been the subject of a number of recent analyst reports. Morgan Stanley downgraded Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $56.00 to $11.00 in a report on Monday, January 27th. HC Wainwright assumed coverage on Intellia Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $30.00 target price for the company. Oppenheimer cut their price target on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. Wedbush reiterated a “neutral” rating and issued a $10.00 price objective (down previously from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Finally, Citigroup increased their target price on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $36.68.

Intellia Therapeutics Price Performance

NTLA opened at $8.31 on Friday. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The company’s 50-day moving average is $8.66 and its 200 day moving average is $11.81. The firm has a market capitalization of $860.23 million, a P/E ratio of -1.53 and a beta of 2.23.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.